Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

FranceBack to France

Clinical trials in Lyon – page 91

1 204 clinical trials in Lyon, France across 7 research sites. Every trial is listed in the EU Clinical Trials Register and updated daily.

FranceOur site in FranceEssaisCliniques.fr(opens in a new tab)
Lyon at a glance
1 204
clinical trials
  • Research sites7
Type of trial
Recruitment status
Quick filters

1 204 trials in Lyon

Open in trial search

Leiomyosarcoma metastatic

Not recruiting

Study of Lurbinectedin and Doxorubicin for First-line Treatment in Patients with Metastatic Leiomyosarcoma

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Filgrastim
  • Sponsor:Pharma Mar S.A.

Acute lymphocytic leukaemia recurrent

Not recruiting

Study of Inotuzumab Ozogamicin Alone and with Drug Combination for Children with Relapsed or Refractory Acute Lymphoblastic Leukemia

Registered drugNo placebo
Countries:FranceFrance
  • Participants:0–17 years
  • Substances:Inotuzumab Ozogamicin
  • Sponsor:Erasmus Universitair Medisch Centrum Rotterdam (Erasmus MC)

Pancreatic carcinoma+3

Not recruiting

Study on BI 907828 for Patients with Advanced Biliary Tract, Pancreatic, Lung, or Bladder Cancer

InvestigationalNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:(3S,3'S,3A's,10A's)-6-Chloro-3'-(3-Chloro-2-Fluorophenyl)-1'-(Cyclopropylmethyl)-6'-Methyl-2-Oxo-1,2,3',3A',10',10A'-Hexahydro-1'H-Spiro[Indole-3,2'-Pyrrolo[2',3':4,5]Pyrrolo[1,2-B]Indazole]-7'-Carboxylic Acid
  • Sponsor:Boehringer Ingelheim Espana S.A.

Neoplasm

Not recruiting

Study of Favezelimab Combined with Pembrolizumab (MK-4280A) for Patients with Selected Solid Tumors

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Favezelimab
  • Sponsor:Merck Sharp & Dohme LLC

Clear cell renal cell carcinoma

Not recruiting

Study of Belzutifan and Pembrolizumab for Patients with Renal Cell Carcinoma After Surgery

Registered drug
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Belzutifan
  • Sponsor:Merck Sharp & Dohme LLC

Systemic lupus erythematosus

Not recruiting

Study on the Effects of Upadacitinib in Adults with Moderate to Severe Systemic Lupus Erythematosus (SLE)

Investigational
Countries:FranceFrance
  • Participants:18–64 years
  • Substances:Upadacitinib
  • Sponsor:AbbVie Deutschland GmbH & Co. KG

Bladder transitional cell carcinoma+2

Not recruiting

Study of Enfortumab Vedotin and Pembrolizumab for Patients with Advanced or Metastatic Urothelial Cancer

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Carboplatin
  • Sponsor:Seagen Inc.

Hidradenitis

Not recruiting

Study on Izokibep for Patients with Moderate to Severe Hidradenitis Suppurativa

Investigational
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Izokibep
  • Sponsor:Acelyrin Inc.

Alport's syndrome

Not recruiting

Study on the Safety and Effects of Setanaxib for Patients with Alport Syndrome

Investigational
Countries:FranceFrance
  • Participants:18–64 years
  • Substances:Setanaxib
  • Sponsor:Calliditas Therapeutics Suisse S.A.

B-cell type acute leukaemia

Not recruiting

Study on the Safety of Epcoritamab for Children and Young Adults with Relapsed or Refractory Aggressive B-cell Lymphomas

InvestigationalNo placebo
Countries:FranceFrance
  • Participants:0–17 years
  • Substances:Epcoritamab
  • Sponsor:AbbVie Deutschland GmbH & Co. KG

Hodgkin's disease

Not recruiting

Study of Pembrolizumab with Chemotherapy for Children and Young Adults with Classical Hodgkin Lymphoma Not Responding Well to Initial Treatment

Registered drugNo placebo
Countries:FranceFrance
  • Participants:0–17 years · 18–64 years
  • Substances:Bleomycin
  • Sponsor:Merck Sharp & Dohme LLC

Study of Ravulizumab for Children with Thrombotic Microangiopathy After Stem Cell Transplant

Not recruiting
Registered drugNo placebo
Countries:FranceFrance
  • Participants:0–17 years
  • Substances:Ravulizumab
  • Sponsor:Alexion Pharmaceuticals Inc.

Other cities in France

The busiest research cities in the country

All 382 cities in France

Clinical research in Lyon

What the registry says about research in the country

01 Oncology Research

Innovative clinical trials focusing on advanced cancer treatments, including studies for endometrial carcinoma, bladder cancer, and various solid tumors. Current research explores combination therapies with novel immunotherapy approaches.

  • Triple-negative breast cancer treatments
  • Gastric and esophageal cancer therapies
  • Advanced pancreatic adenocarcinoma

Multiple studies are evaluating targeted therapies and immunological approaches for various tumor types.

02 Immunology and Infectious Diseases

Groundbreaking research in immune system modulation and infectious disease prevention, including studies on COVID-19 vaccines and immune response in critical conditions.

  • Novel COVID-19 intranasal vaccine development
  • Yellow fever vaccine studies
  • ICU-acquired immunosuppression treatment

Focus on developing innovative vaccination strategies and immune system interventions.

03 Chronic Conditions

Studies addressing long-term health conditions, with particular emphasis on kidney disease, cardiovascular health, and metabolic disorders.

  • Chronic kidney disease management
  • Heart failure prevention
  • Hypertriglyceridemia treatment

Innovative approaches combining established and experimental treatments for improved patient outcomes.

Back to FranceAll countries
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.